治疗2型糖尿病新药——维格列汀  

Vildagliptin in treatment of type 2 diabetes mellitus

作　　者：安富荣[1] 崔岚[1] 王勤[1] 

机构地区：[1]上海交通大学医学院附属仁济医院药剂科,上海200001

出　　处：《中国新药与临床杂志》2012年第10期574-578,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：维格列汀是一种口服给药的二肽基肽酶Ⅳ抑制剂,能减少胰高血糖素样肽1的分解,增强其促进胰岛β细胞分泌胰岛素的活性,抑制胰高血糖素的分泌。维格列汀单独用药可改善血糖控制,与二甲双胍、磺脲类、噻唑烷二酮类药物联合应用可增强疗效,并且不增加低血糖的风险,也不增加体重。本文对维格列汀的作用机制、药动学特性、临床研究进展以及安全性等作一综述。Vildagliptin is an orally administered selective inhibitor of dipeptidyl peptidase Ⅳ.Vildagliptin reduces the degradation of the glucagon-like peptide 1, thereby enhancing its actions, and is associated with improved beta-cell function and suppression of glucagon secretion. Clinical trials have shown that vildagliptin improves glycemic control in monotherapy and provides additional efficacy when used in combination with other oral antidiabetic agents （metformin, sulfonylurea, thiazolidinedione）. Vildagliptin is associated with a low risk of hypoglycaemia and is weight neutral. The mechanism of action, pharmacokinetic properties, the new advances in clinical trails, and safety of vildagliptin are reviewed in this article.

关 键 词：维格列汀 糖尿病 2型 抗原 CD26 二肽基肽酶Ⅳ抑制剂 

分 类 号：R977.15[医药卫生—药品]